| scholarly article | Q13442814 |
| P2093 | author name string | Daniel L Alkon | |
| Martin R Farlow | |||
| Lee-Jen Wei | |||
| Richard E Thompson | |||
| David Crockford | |||
| Susanne Wilke | |||
| Alan J Tuchman | |||
| Elaine Grenier | |||
| Jeffrey Benison | |||
| P2860 | cites work | Postischemic PKC activation rescues retrograde and anterograde long-term memory | Q24646400 |
| “Mini-mental state” | Q25938989 | ||
| Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 | ||
| Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer's Disease Phase IIa and Expanded Access Trials | Q33708951 | ||
| Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease | Q33911859 | ||
| An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. | Q34433716 | ||
| Loss in PKC Epsilon Causes Downregulation of MnSOD and BDNF Expression in Neurons of Alzheimer's Disease Hippocampus. | Q54979994 | ||
| Phase II study of bryostatin 1 in patients with relapsed multiple myeloma | Q74524894 | ||
| The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. | Q34433720 | ||
| Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains | Q34596733 | ||
| Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study | Q34746698 | ||
| A focus on the synapse for neuroprotection in Alzheimer disease and other dementias | Q35914866 | ||
| Immunology and immunotherapy of Alzheimer's disease | Q36460445 | ||
| Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. | Q36568086 | ||
| PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease | Q36705548 | ||
| Randomized phase II designs. | Q37173942 | ||
| Towards universal therapeutics for memory disorders | Q38470188 | ||
| Reduction of beta-amyloid levels by novel protein kinase C(epsilon) activators | Q39784350 | ||
| Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon | Q42084058 | ||
| Memantine in moderate-to-severe Alzheimer's disease | Q44388745 | ||
| PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer's disease transgenic mice | Q44962410 | ||
| Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment | Q48694961 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| bryostatin | Q4981136 | ||
| placebo | Q269829 | ||
| memantine | Q412189 | ||
| P304 | page(s) | 555-570 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease | |
| P478 | volume | 67 |
| Q89690206 | Born to Protect: Leveraging BDNF Against Cognitive Deficit in Alzheimer's Disease |
| Q100945954 | Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice |
| Q93057430 | Munc13 Is a Molecular Target of Bryostatin 1 |
| Q64880531 | Natural Compounds for Alzheimer's Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. |
| Q91710367 | Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty |
Search more.